EUCTR2006-004407-19-LT进行中（未招募）不适用
A multi-center, double-blind, randomized, placebo controlled, dose-ranging phase 2 study to investigate pharmacodynamics, safety, tolerability and pharmacokinetics of RO5073031 in patients with type 2 diabetes mellitus treated with a stable dose of metformin (BC20688)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Type 2 diabetes mellitus patients treated with individual maximum tolerated daily dose of metformin monotherapy (metformin daily dose = 1.5 g, maximum not higher than recommended in the label) for at least 3 months prior to screening.
- •-Males, postmenopausal women (defined as more than two years after the cessation of menses) or surgically sterilized women.
- •-Age 18 to 75 years at the time of the screening examination.
- •-HbA1c = 7.0 % and = 9.5 % at screening.
- •-Fasting plasma glucose (FPG) > 126 mg/dL (7.0 mmol/L) and = 240 mg/dL (13.3 mmol/L) at screening.
- •-BMI > 25 kg/m2 and = 45 kg/m2 at screening
- •-Stable weight ± 10% for at least 3 months before screening.
- •-Patients able and willing to give written informed consent and to comply with the requirements of the study (patients that cannot follow blood glucose selfmonitoring and study requirements independently from another person cannot be included).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Type 1 diabetes mellitus patients
- •-Known hypersensitivity to RO5073031 or any of its components.
- •-Known contraindications to metformin, i.e.
- •-Congestive heart failure requiring pharmacologic treatment;
- •-Clinically significant respiratory insufficiency.
- •-History of ketoacidosis or lactic acidosis.
- •-Treatment with any anti-hyperglycemic medication other than metformin monotherapy during the last 3 months (except insulin use in acute situations or
- •during surgery for up to 7 days).
- •-Any previous exposure to GLP-1, GLP-1 analogues or exenatide before the study.
- •-Systemic use of corticosteroids in the last 3 months.
- •-Use of weight lowering medications (orlistat, sibutramine, rimonabant, phentermine) in the last 3 months.
- •-Patients receiving ACE inhibitors, beta-blockers, thiazide diuretics, thyroid hormones, and/or lipid lowering medications who are not on a stable dose for
- •more than 6 weeks prior to the start of the study.
- •-Impaired liver function (ALAT or ASAT or total bilirubin or alkaline phosphatase > 2.5x ULN) at screening.
- •-Renal disease or renal dysfunction (as suggested by serum creatinine levels = 1.5 mg/dL [males], = 1.4 mg/dl [females]) at screening.
- •-Uncontrolled hypertension (SBP > 160 mmHg and/or DBP > 100 mmHg, despite treatment) at the time of the screening examination.
- •-Myocardial infarction or stroke within 6 months prior to the screening examination.
- •-Known hemoglobinopathy.
- •-Known proliferative diabetic retinopathy.
- •-Clinically significant GI disease including inflammatory bowel disease, irritable bowel
- •syndrome, celiac disease, dyspepsia, apparent diabetic gastroparesis, diabetic diarrhoea, or surgery of the gastro-intestinal tract (except appendectomy / cholecystectomy).
- •-Any abnormality in clinical laboratory tests or ECG, which precludes safe involvement in the study as judged by the investigator.
- •-Pregnant or lactating women or women of childbearing potential.
- •-Participation in an investigational drug study within 90 days [3 months] (or treatment with any investigational agent within five half-lives of that investigational drug, whichever is longer) prior to screening.
- •-Serious illness, such as active cancer, major active infection, severe psychiatric disorders at the time of the screening examination.
- •-Alcohol or drug abuse.
研究者
相似试验
已完成
不适用
Comparison of Adapalene and Benzoyl Peroxide Gel from Cadila Pharmaceuticals Limited with Epiduo�® Forte (Adapalene and Benzoyl Peroxide) Gel from Galderma Laboratories, L.P. in the treatment of acne vulgarisCTRI/2020/11/028801Cadila Pharmaceuticals Limited500
进行中（未招募）
1 期
Coronary computed tomography study to assess the effect of inclisiran on atherosclerotic plaque progression in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular eventson-obstructive coronary artery diseaseMedDRA version: 20.0Level: PTClassification code 10011078Term: Coronary artery diseaseSystem Organ Class: 10007541 - Cardiac disordersEUCTR2021-004601-47-IEovartis Pharma AG600
进行中（未招募）
1 期
Coronary computed tomography study to assess the effect of inclisiran on atherosclerotic plaque progression in participants with a diagnosis of non-obstructive coronary artery disease without previous cardiovascular eventsEUCTR2021-004601-47-HUovartis Pharma AG600
进行中（未招募）
1 期
Efficacy and Safety study of CSJ148 in stem cell transplant patientshuman cytomegalovirus (HCMV) in stem cell transplant patientsMedDRA version: 17.1Level: LLTClassification code 10009703Term: CMV infectionSystem Organ Class: 100000004862EUCTR2014-002150-39-BEovartis Pharma Services AG86
进行中（未招募）
1 期
A multi-center, randomized, double-blind, placebo and active controlled, parallel group study to evaluate the dose response of AHU377 in combination with valsartan 320 mg after 8 week treatment in patients with mild-to-moderate systolic hypertensioessential hypertensionMedDRA version: 13.1Level: PTClassification code 10015488Term: Essential hypertensionSystem Organ Class: 10047065 - Vascular disordersEUCTR2010-022326-32-SKovartis Pharma Services AG910